Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Basal Ganglia Diseases

ClinicalTrials.gov lists 5,475 trials for Basal Ganglia Diseases or a narrower condition beneath it. National Institute of Neurological Disorders and Stroke (NINDS) has the most among industry and government lead sponsors, with 77.

MeSH D001480 Nervous System Diseases C10
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 499 Phase 1/2 Phase 1/2 137 Phase 2 Phase 2 619 Phase 2/3 Phase 2/3 71 Phase 3 Phase 3 307 Phase 4 Phase 4 204 Not applicable Not applicable 2,268 Observational Observational 1,354 Phase 1 Phase 1 499 Phase 1/2 Phase 1/2 137 Phase 2 Phase 2 619 Phase 2/3 Phase 2/3 71 Phase 3 Phase 3 307 Phase 4 Phase 4 204 Not applicable Not applicable 2,268 Observational Observational 1,354

Trials per phase (log scale)

2 more sections with rows

40 of the 5,475 trials are tagged with Basal Ganglia Diseases itself; the rest are tagged with a narrower condition beneath it.

Get the Basal Ganglia Diseases report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Basal Ganglia Diseases trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 11 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 405

1990: 2 trials (Observational 2) 1991: 1 trials (Observational 1) 1992: 4 trials (Observational 2, Phase 4 1, Phase 2 1) 1993: 6 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 2 2) 1994: 5 trials (Not applicable 2, Phase 3 2, Phase 2 1) 1995: 4 trials (Observational 2, Not applicable 1, Phase 3 1) 1996: 2 trials (Observational 1, Phase 2 1) 1997: 7 trials (Observational 4, Phase 3 1, Phase 2 2) 1998: 11 trials (Observational 4, Not applicable 2, Phase 4 1, Phase 3 3, Phase 2 1) 1999: 12 trials (Observational 2, Not applicable 1, Phase 3 4, Phase 2/3 1, Phase 2 4) 2000: 23 trials (Observational 7, Not applicable 1, Phase 4 1, Phase 3 4, Phase 2 7, Phase 1 3) 2001: 23 trials (Observational 8, Not applicable 1, Phase 3 5, Phase 2 3, Phase 1/2 2, Phase 1 4) 2002: 37 trials (Observational 11, Not applicable 5, Phase 4 3, Phase 3 7, Phase 2/3 2, Phase 2 8, Phase 1/2 1) 2003: 49 trials (Observational 14, Not applicable 3, Phase 4 3, Phase 3 9, Phase 2/3 1, Phase 2 13, Phase 1/2 1, Phase 1 5) 2004: 71 trials (Observational 17, Not applicable 9, Phase 4 4, Phase 3 17, Phase 2/3 2, Phase 2 17, Phase 1/2 1, Phase 1 4) 2005: 68 trials (Observational 12, Not applicable 9, Phase 4 7, Phase 3 12, Phase 2 18, Phase 1/2 2, Phase 1 8) 2006: 111 trials (Observational 34, Not applicable 12, Phase 4 14, Phase 3 13, Phase 2/3 3, Phase 2 23, Phase 1/2 3, Phase 1 9) 2007: 110 trials (Observational 20, Not applicable 17, Phase 4 16, Phase 3 22, Phase 2/3 4, Phase 2 24, Phase 1/2 1, Phase 1 6) 2008: 104 trials (Observational 23, Not applicable 18, Phase 4 9, Phase 3 14, Phase 2/3 4, Phase 2 19, Phase 1/2 5, Phase 1 12) 2009: 155 trials (Observational 32, Not applicable 26, Phase 4 15, Phase 3 22, Phase 2/3 3, Phase 2 18, Phase 1/2 8, Phase 1 31) 2010: 134 trials (Observational 37, Not applicable 32, Phase 4 6, Phase 3 17, Phase 2/3 3, Phase 2 23, Phase 1/2 4, Phase 1 12) 2011: 153 trials (Observational 40, Not applicable 32, Phase 4 13, Phase 3 16, Phase 2/3 3, Phase 2 24, Phase 1/2 5, Phase 1 20) 2012: 149 trials (Observational 41, Not applicable 44, Phase 4 12, Phase 3 9, Phase 2/3 3, Phase 2 21, Phase 1/2 6, Phase 1 13) 2013: 182 trials (Observational 57, Not applicable 69, Phase 4 7, Phase 3 12, Phase 2/3 2, Phase 2 14, Phase 1/2 3, Phase 1 18) 2014: 209 trials (Observational 39, Not applicable 96, Phase 4 9, Phase 3 12, Phase 2/3 2, Phase 2 16, Phase 1/2 2, Phase 1 33) 2015: 234 trials (Observational 50, Not applicable 112, Phase 4 3, Phase 3 10, Phase 2/3 3, Phase 2 28, Phase 1/2 5, Phase 1 23) 2016: 226 trials (Observational 42, Not applicable 106, Phase 4 12, Phase 3 6, Phase 2/3 2, Phase 2 37, Phase 1/2 1, Phase 1 20) 2017: 239 trials (Observational 61, Not applicable 105, Phase 4 10, Phase 3 7, Phase 2/3 2, Phase 2 25, Phase 1/2 9, Phase 1 20) 2018: 296 trials (Observational 65, Not applicable 126, Phase 4 7, Phase 3 14, Phase 2/3 4, Phase 2 39, Phase 1/2 10, Phase 1 31) 2019: 335 trials (Observational 78, Not applicable 161, Phase 4 10, Phase 3 16, Phase 2/3 1, Phase 2 29, Phase 1/2 6, Phase 1 34) 2020: 302 trials (Observational 80, Not applicable 144, Phase 4 4, Phase 3 11, Phase 2/3 2, Phase 2 27, Phase 1/2 5, Phase 1 29) 2021: 405 trials (Other 1, Observational 110, Not applicable 213, Phase 4 7, Phase 3 6, Phase 2/3 5, Phase 2 34, Phase 1/2 7, Phase 1 22) 2022: 337 trials (Observational 92, Not applicable 168, Phase 4 6, Phase 3 5, Phase 2/3 3, Phase 2 28, Phase 1/2 8, Phase 1 27) 2023: 366 trials (Observational 105, Not applicable 186, Phase 4 9, Phase 3 5, Phase 2/3 4, Phase 2 26, Phase 1/2 7, Phase 1 24) 2024: 362 trials (Observational 91, Not applicable 198, Phase 4 3, Phase 3 6, Phase 2/3 3, Phase 2 26, Phase 1/2 6, Phase 1 29) 2025: 363 trials (Observational 93, Not applicable 190, Phase 4 4, Phase 3 6, Phase 2/3 4, Phase 2 25, Phase 1/2 14, Phase 1 27)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 337
2025 363
2024 362
2023 366
2022 337
2021 405
2020 302
2019 335
2018 296
2017 239

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 400 trials starting in 2026 and about 380 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 567 trials still running at the 2026-10-09 snapshot; registered median of 22 months across 3,140 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Basal Ganglia Diseases trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 499
Phase 1/2 137
Phase 2 619
Phase 2/3 71
Phase 3 307
Phase 4 204
Not applicable 2,268
Observational 1,354
Expanded access 15
Unknown 1

How many Basal Ganglia Diseases trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 240
Recruiting 771
Enrolling by invitation 91
Active, not recruiting 196
Available 4

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Basal Ganglia Diseases trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Institute of Neurological Disorders and Stroke (NINDS) 77
Bial - Portela C S.A. 56
Boehringer Ingelheim 44
VA Office of Research and Development 42
AbbVie 33

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Basal Ganglia Diseases? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Levodopa 49
BIA 9-1067 40
KW-6500 32
Istradefylline 19
Droxidopa 19

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Group R Rasagiline 50
Rotigotine TTS (Test) 39
Pramipexole ER 36
Exercise 34
Transcranial Magnetic Stimulation 24

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Basal Ganglia Diseases trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Fall 346 90
Overnight hospitalization 334 1
Pneumonia 299 103
Parkinson's disease 237 37
Syncope 176 69

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Basal Ganglia Diseases? (125)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
The effects of etidronate on brain calcifications in Fahr's disease or syndrome: rationale and design of the randomised, placebo-controlled, double-blind CALCIFADE trial. Orphanet journal of rare diseases 2024 Yes
Long-Term Improvement and Safety of Aripiprazole for Irritability and Adaptive Function in Asian Children and Adolescents with Autistic Disorder: A 52-Week, Multinational, Multicenter, Open-Label Study. Journal of child and adolescent psychopharmacology 2022 Yes
Comparison of Integrated Outpatient Palliative Care With Standard Care in Patients With Parkinson Disease and Related Disorders: A Randomized Clinical Trial. JAMA neurology 2020 Yes
Familial deep cavitating state with a glutathione metabolism defect. Annals of clinical and translational neurology 2019 Yes
Extrapyramidal side effects of antipsychotics are linked to their association kinetics at dopamine D<sub>2</sub> receptors. Nature communications 2017 Yes

Showing 5 of 125 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (11)

MeSH descendants one level down with at least one trial, most trials first.

+1 more sub-condition

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages